Clik here to view.
Novo nabs over a third of diabetes market, a year ahead of schedule
Novo Nordisk’s GLP-1 drugs may have been the center of attention during its first-quarter earnings call, but the company’s broader diabetes portfolio beat its target for a greater global market stake...
View ArticleClik here to view.
ICER pushes back on FDA's potential conversion of Sarepta's gene therapy to...
The integrity of the FDA’s accelerated approval process should be called into question if the agency grants full approval to treatments that have failed their required confirmatory trials, the chief...
View ArticleAstraZeneca's Calquence hits endpoint in first-line mantle cell lymphoma trial
AstraZeneca is working on moving its BTK inhibitor Calquence into earlier stages of mantle cell lymphoma, releasing what it calls positive interim results from a Phase 3 trial. The combo of Calquence...
View ArticlePharma companies soften tone on full IRA impact
Despite the pharmaceutical industry’s heavy criticism of the Inflation Reduction Act, Johnson & Johnson, Pfizer and Bristol Myers Squibb recently downplayed the legislation’s overall impact on...
View ArticleAmgen touts new data for drug MariTide, moving rapidly into Phase 3 work
Amgen said that an interim look at a Phase 2 trial of its anti-obesity drug MariTide had left the company “very encouraged,” and it planned to rapidly move forward with a final-stage program as well as...
View ArticleClik here to view.
Lonnel Coats announces retirement from Lexicon; Another shakeup in Vir's C-suite
Lonnel Coats → Lexicon Pharmaceuticals CEO Lonnel Coats will retire July 7, 10 years to the day after accepting the job. Lexicon overcame numerous regulatory obstacles with its SGLT1/2 inhibitor...
View ArticleBipartisan draft bill would pay hospitals more to combat drug shortages
The Senate Finance Committee released a new bipartisan draft legislation on Friday morning that would incentivize generic manufacturers and healthcare providers, like hospitals and clinics, to mitigate...
View ArticleClik here to view.
AEON fails another migraine trial, shares halve as company reviews options
AEON Biopharma said its botulinum toxin treatment candidate failed a Phase 2 migraine study at the planned interim analysis. The company’s share price $AEON was halved in premarket trading on Friday....
View ArticleRoyalty Pharma's milestone payment to Arrowhead; Abeona's $75M offering
Plus, news about Soleno, Novo Nordisk and Cardior Pharmaceuticals: Royalty Pharma pays Arrowhead Pharmaceuticals: The $50 million milestone payment comes after the completed enrollment of a Phase 3...
View ArticleRo CEO Zachariah Reitano talks GLP-1 drug pricing, shortages and compounded...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) The fight to dominate the market for weight loss shots has never been hotter, but drugmakers still can’t...
View ArticleClik here to view.
CG Oncology touts interim Phase 3 bladder cancer data as it gears up to...
An experimental oncolytic virus therapy developed by CG Oncology helped clear tumors in 75% of bladder cancer patients in a Phase 3 study. The therapy, known as cretostimogene grenadenorepvec, or creto...
View ArticleFTC wants more information on Novo-Catalent deal in antitrust review
The Federal Trade Commission has extended its antitrust review of Novo Holdings’ $16.5 billion purchase of Catalent by potentially another 30 days as it requests additional information. Both the...
View ArticleHouse to mark up bill targeting Chinese biotech and genomics companies
The House Oversight Committee will mark up a far-reaching bill on May 15 that, if passed, could force many US biopharma companies to cut ties with WuXi and several other Chinese life sciences...
View ArticleClik here to view.
AbbVie puts $161M into new R&D site in Germany, will add 300 jobs
AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany which it expects to complete in 2027, the company announced this week. At a...
View ArticleClik here to view.
Senators from both parties introduce menopause research bill
A group of Democratic and Republican senators introduced a bill on Thursday that calls for $275 million toward federal menopause research and awareness efforts over five years. The legislation would...
View ArticleJ&J showcases more bladder cancer results from 'pretzel' drug-device combo
Updated data from a trial of Johnson & Johnson’s experimental “pretzel” showed that more than 80% of bladder cancer patients who got the treatment saw their tumors melt away, building on a readout...
View ArticleNovartis’ radiopharma gambit; Weight loss battle plays out; Spark...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleUPenn and Stanford analysis finds no secondary cancer cases directly due to...
The University of Pennsylvania’s pioneering cell therapy physician Carl June shared new data Monday that showed the risk of secondary cancers following CAR-T therapy was very low. In over 1,500...
View ArticleIllumina takes a step toward spinning off Grail, though keeps option open for...
Illumina prefers to spin off Grail into an independent business rather than sell the cancer diagnostics company, according to a financial document released Monday that describes the Illumina board’s...
View ArticleClik here to view.
Vertex touts Casgevy sickle cell launch as bluebird makes progress with rival...
Vertex said it’s making strong progress bringing its CRISPR Therapeutics-partnered gene therapy to patients after a landmark approval for sickle cell disease in December. Chief operating officer Stuart...
View Article